Effect of Epidermal Growth Factor Receptor Mutations on the Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Target-Based Populations for Target-Based Drugs-Reference-Cited by-同舟云学术

Effect of Epidermal Growth Factor Receptor Mutations on the Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Target-Based Populations for Target-Based Drugs

Published:2004-12 Issue: Volume:6 Page:S35-S42
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Calvo Emiliano,Rowinsky Manuel K.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference57 articles.

1. Epidermal growth factor receptor as a target to improve treatment of lung cancer;Andratschke;Clin Lung Cancer,2004

2. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with nonsmall cell lung cancer: a randomized trial;Kris;JAMA,2003

3. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer;Fukuoka;J Clin Oncol,2003

4. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 1;Giaccone;J Clin Oncol,2004

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Drug Monitoring of Erlotinib in Non-Small Cell Lung Carcinoma: A Case Study;Therapeutic Drug Monitoring;2021-08

2. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages;Journal of Hematology & Oncology;2017-05-04

3. Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer Care;Therapeutic Drug Monitoring;2014-06

4. Tissue is alive: New technologies are needed to address the problems of protein biomarker pre-analytical variability;PROTEOMICS - Clinical Applications;2009-08

5. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor;Molecular Cancer Therapeutics;2009-06